On Demand Webinars
Mitigation and identification of aggregation and nonspecific reactivity interference in high-throughput screeningContains 2 Component(s) Recorded On: 06/07/2018
Compound-mediated assay interference and bioassay promiscuity are significant burdens in drug and chemical probe discovery. Pursuing artifacts or poorly tractable, nonselective chemical matter from real and virtual high-throughput screening (HTS) can waste significant scientific resources and can lead to tenuous scientific conclusions when used in subsequent studies.
Using AI and IoT to Accelerate ResearchContains 2 Component(s) Recorded On: 05/08/2018
In this webinar, we will explore how new technologies can be used to accelerate scientific research. Join us for an in-depth look at how we can also overcome challenges by practically incorporating new tech into research processes to uncover and decipher hidden confounding variables.
In-house software and processes to support High Content Screening of Primary NeuronsContains 1 Component(s) Recorded On: 02/07/2018
This presentation will focus on the development and implementation of novel in-house software utilities used at Scripps Florida to support the Synaptogenesis neuroscience drug discovery project.
Inline, Label-free Detection Using the Droplet Frequency SensorContains 1 Component(s) Recorded On: 02/07/2018
Inline detectors are extensively used in chemical separations and other life sciences workflows to quantify analytes based on fundamental properties.
Open development from user to vendor and back again; how everybody winsContains 1 Component(s) Recorded On: 02/07/2018
This presentation will discuss how this ‘overlap’ can be leveraged to produce better products, better interaction and better results for all parties. This presentation will explore opportunities to further these aims and bring the supplier and user of everyday laboratory equipment together.
Large scale profiling in human primary-cell based phenotypic assays identifies novel outcome pathways for drug efficacy in cardiovascular diseaseContains 1 Component(s) Recorded On: 02/07/2018
Findings support the value of a large chemical biology database of reference drugs profiled through primary human cell-based phenotypic assays. This database has been mined to reveal several novel associations with adverse events and identified potential mechanisms of toxicity, and here we show how this database can be used to generate new hypotheses for drug efficacy.
HIPStA, a High Throughput Alternative to CETSAContains 1 Component(s) Recorded On: 02/07/2018
This presentation reviews data demonstrating the proof of concept for the HIPStA method, using 3 different classes of drug discovery targets: Receptor tyrosine kinases, Nuclear Hormone Receptors and Cytoplasmic Protein Kinases. HIPStA represents a more scale-able alternative to CETSA for detecting drug-target interaction in cells.
New Functional Genomics toolsets: Arrayed loss of function screening with LentiArray CRISPR librariesContains 1 Component(s) Recorded On: 02/07/2018
Here we demonstrate a knock-out screening approach that utilizes the Invitrogen™ LentiArray™ CRISPR library to interrogate the impact of individual gene knock-outs on the NFκB pathway as measured by a functional cell-based assay. We describe the library design concepts, the assay development, initial screening results and validation of specific identified hits.
Next generation target discovery: systematic application of the CRISPR toolkitContains 1 Component(s) Recorded On: 02/07/2018
Forward genetic screening with CRISPR–Cas9 has provided a promising new way to interrogate the phenotypic consequences of gene manipulation in high-throughput, unbiased analyses in target ID, target validation, drug MOA analysis and patient stratification. Diseases previously refractory to systematic high-throughput interrogation are now coming into the cross-hairs of powerful new functional genomic solutions.
Current landscape and future opportunities in implementing human microphysiological models in pre-clinical drug developmentContains 1 Component(s) Recorded On: 02/07/2018
The presentation provide a perspective on the breadth of new opportunities available for the integration of 3D human in vitro models within drug discovery and the related challenges in adoption. It will introduce key technological background and advantages/limitations of each novel 3D human in vitro models with examples from recent studies or cases.